Diarrhea News and Research RSS Feed - Diarrhea News and Research

Diarrhea is loose, watery stools. A person with diarrhea typically passes stool more than three times a day. People with diarrhea may pass more than a quart of stool a day. Acute diarrhea is a common problem that usually lasts 1 or 2 days and goes away on its own without special treatment. Prolonged diarrhea persisting for more than 2 days may be a sign of a more serious problem and poses the risk of dehydration. Chronic diarrhea may be a feature of a chronic disease.

Diarrhea can cause dehydration, which means the body lacks enough fluid to function properly. Dehydration is particularly dangerous in children and older people, and it must be treated promptly to avoid serious health problems.
Astellas reports topline results from isavuconazole Phase 3 study in candidemia and other invasive Candida infections

Astellas reports topline results from isavuconazole Phase 3 study in candidemia and other invasive Candida infections

Astellas today announced topline results from the Phase 3 ACTIVE study evaluating the efficacy and safety of intravenous (IV) and oral isavuconazole, commercially known as CRESEMBA (isavuconazonium sulfate), under development for adults with candidemia and other invasive Candida infections. [More]
Hand washing tips to protect against many infections

Hand washing tips to protect against many infections

As the beginning of the school year approaches, parents need to remind their children about the importance of hand washing. Every day people touch several surfaces including books, desks, door knobs, sink handles, and other people and many of them harbor germs like bacteria and viruses that can cause illnesses. [More]
Novartis announces FDA approval of Odomzo (sonidegib) 200 mg capsules for treatment of laBCC patients

Novartis announces FDA approval of Odomzo (sonidegib) 200 mg capsules for treatment of laBCC patients

Novartis today announced the US Food and Drug Administration has approved Odomzo (sonidegib, formerly LDE225) 200 mg capsules for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. [More]
Amgen announces submission of supplemental New Drug Application to FDA for Kyprolis (carfilzomib)

Amgen announces submission of supplemental New Drug Application to FDA for Kyprolis (carfilzomib)

Amgen today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Kyprolis (carfilzomib) for Injection to seek an expanded indication for the treatment of patients with a form of blood cancer, relapsed multiple myeloma, who have received at least one prior therapy. [More]
Georgia researchers develop new tools to genetically manipulate parasite that causes cryptosporidiosis

Georgia researchers develop new tools to genetically manipulate parasite that causes cryptosporidiosis

Researchers at the University of Georgia have developed new tools to study and genetically manipulate cryptosporidium, a microscopic parasite that causes the diarrheal disease cryptosporidiosis. [More]
IMBRUVICA (ibrutinib) approved in Europe for treatment of Waldenstrom's macroglobulinemia

IMBRUVICA (ibrutinib) approved in Europe for treatment of Waldenstrom's macroglobulinemia

Today AbbVie announced the European Commission granted marketing authorization for IMBRUVICA (ibrutinib) as the first treatment option available in all 28 member states of the European Union for the treatment of Waldenstrom's macroglobulinemia (WM), a rare, slow growing blood cancer, in adult patients who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. [More]
Envarsus XR receives FDA approval for treatment of kidney transplant recipients

Envarsus XR receives FDA approval for treatment of kidney transplant recipients

Veloxis Pharmaceuticals A/S today announced U.S. Food and Drug Administration approval of Envarsus XR (tacrolimus extended-release tablets) for the prophylaxis of rejection in kidney transplant patients who require or desire conversion from other twice-daily tacrolimus products to once-daily Envarsus XR. [More]
UTHealth scientist receives $1.9 million from NIH to develop non-antibiotic treatment for C. diff infections

UTHealth scientist receives $1.9 million from NIH to develop non-antibiotic treatment for C. diff infections

Charles Darkoh, Ph.D., a researcher at The University of Texas Health Science Center at Houston School of Public Health, was recently awarded a five-year, $1.9 million R01 grant by the National Institutes of Health to develop a non-antibiotic treatment for Clostridium difficile (C. diff) infections. [More]
Tillotts Pharma to purchase global rights for AstraZeneca’s Entocort excluding the U.S.

Tillotts Pharma to purchase global rights for AstraZeneca’s Entocort excluding the U.S.

Tillotts Pharma AG, part of the Zeria Group, announced today that it has entered into an agreement for the acquisition of the global rights for Entocort (budesonide) from AstraZeneca, excluding the U.S., which will remain with AstraZeneca. [More]
Two new studies show that fecal transplantation may help fight against ulcerative colitis

Two new studies show that fecal transplantation may help fight against ulcerative colitis

Two new studies led by researchers from the Farncombe Family Digestive Health Research Institute at McMaster University show that transplantation of fecal matter may be a useful tool in the fight against ulcerative colitis (UC). [More]
Paclitaxel-fostamatinib combination therapy may reduce size of ovarian cancer cells

Paclitaxel-fostamatinib combination therapy may reduce size of ovarian cancer cells

Working in cell cultures and mice, researchers at Johns Hopkins have found that an experimental drug called fostamatinib combined with the chemotherapy drug paclitaxel may overcome ovarian cancer cells' resistance to paclitaxel. [More]
Study provides insights into the cause of irritable bowel syndrome

Study provides insights into the cause of irritable bowel syndrome

A team comprised of scientists at VIB, KU Leuven and UZ Leuven has made significant progress in uncovering the connection between psychological factors and the immune system. Their findings are based on an investigation of a massive drinking water contamination incident in Belgium in 2010, and are now published in the leading international medical journal Gut. [More]
Extreme heat and precipitation events linked to increased risk of Salmonella infections

Extreme heat and precipitation events linked to increased risk of Salmonella infections

Extreme heat and precipitation events, which are expected to increase in frequency and intensity due to climate change, are associated with increased risk of Salmonella infections, according to a study led by researchers from the University of Maryland School of Public Health. [More]
Pinaverium offers quick relief from IBS symptoms

Pinaverium offers quick relief from IBS symptoms

Pinaverium offers quick and effective relief of irritable bowel syndrome (IBS) symptoms, according to clinical trial results published in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association. [More]
STIOLTO RESPIMAT Inhalation Spray now available for treatment of COPD across the U.S.

STIOLTO RESPIMAT Inhalation Spray now available for treatment of COPD across the U.S.

Boehringer Ingelheim Pharmaceuticals, Inc. announced today that STIOLTO RESPIMAT (tiotropium bromide and olodaterol) Inhalation Spray is now available by prescription at pharmacies across the United States. [More]
Ron Simon & Associates files salmonella lawsuit against restaurant located in North Carolina

Ron Simon & Associates files salmonella lawsuit against restaurant located in North Carolina

Today the national food safety law firm of Ron Simon & Associates, along with local counsel Janet, Jenner & Suggs, filed a lawsuit stemming from salmonella-contaminated food served by the Tarheel Q located in North Carolina on U.S. 64 West in Lexington. [More]
The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

Eli Lilly and Company announced that The Lancet Oncology has published results of the Phase III REACH trial that evaluated CYRAMZA (ramucirumab) as a second-line treatment for people with hepatocellular carcinoma (HCC), also known as liver cancer. While the REACH trial's primary endpoint of overall survival favored the CYRAMZA arm, it was not statistically significant. [More]
Phase 3 study shows Vectibix meets primary endpoint in patients with chemorefractory wild-type KRAS mCRC

Phase 3 study shows Vectibix meets primary endpoint in patients with chemorefractory wild-type KRAS mCRC

Amgen today announced that a Phase 3 study evaluating Vectibix (panitumumab) and best supportive care (BSC) met its primary endpoint, demonstrating a statistically significant improvement in overall survival (OS) in patients with chemorefractory wild-type KRAS (exon 2) metastatic colorectal cancer (mCRC) compared to those patients treated with BSC alone. [More]
Novartis presents positive Phase III results of Farydak therapy at EHA

Novartis presents positive Phase III results of Farydak therapy at EHA

Novartis today presented results from a pivotal Phase III clinical trial exploratory subgroup analysis showing a 7.8-month improvement in median progression-free survival when using Farydak in combination with bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma who had received two or more prior regimens, including bortezomib and an immunomodulatory agent. [More]
Researchers uncover new mechanism that innate immune system uses to curb viral infections

Researchers uncover new mechanism that innate immune system uses to curb viral infections

An innovative mechanism that the innate immune system uses to control viral infections has been uncovered by researchers at the University Medical Centers in Mainz and Freiburg. Central to this is the discovery that two different but related elements of the immune system can act together in concert to fight, for example, rotavirus infections. [More]
Advertisement